These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38938063)

  • 1. Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
    Anastasilakis AD; Yavropoulou MP; Palermo A; Makras P; Paccou J; Tabacco G; Naciu AM; Tsourdi E
    Eur J Endocrinol; 2024 Jul; 191(1):R9-R21. PubMed ID: 38938063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoanabolic and dual action drugs.
    Tabacco G; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Biochem Pharmacol; 2019 Aug; 166():185-191. PubMed ID: 31136739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension.
    Cosman F; Oates M; Betah D; Timoshanko J; Wang Z; Ferrari S; McClung MR
    J Bone Miner Res; 2024 Sep; 39(9):1268-1277. PubMed ID: 39041711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture.
    Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY
    Semin Arthritis Rheum; 2019 Oct; 49(2):184-196. PubMed ID: 30737062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.
    Canalis E
    Eur J Endocrinol; 2018 Feb; 178(2):R33-R44. PubMed ID: 29113980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
    Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
    BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abaloparatide: A new pharmacological option for osteoporosis.
    Sleeman A; Clements JN
    Am J Health Syst Pharm; 2019 Jan; 76(3):130-135. PubMed ID: 30689744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
    Merlotti D; Falchetti A; Chiodini I; Gennari L
    Expert Opin Pharmacother; 2019 May; 20(7):805-811. PubMed ID: 30856013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
    Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
    Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
    Watts NB; Hattersley G; Fitzpatrick LA; Wang Y; Williams GC; Miller PD; Cosman F
    Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.
    Hong P; Liu R; Rai S; Liu J; Zhou Y; Zheng Y; Li J
    J Orthop Surg Res; 2023 Feb; 18(1):116. PubMed ID: 36797767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
    Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
    Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
    McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
    Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.